Bristol-Myers Squibb Company (BMY)
Profitability ratios
Return on sales
| Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross profit margin | 34.43% | 36.48% | 36.44% | 36.07% | 37.48% | 36.88% | 37.15% | 38.42% | 38.38% | 36.57% | 37.38% | 37.07% | 34.92% | 46.15% | 54.63% | 63.19% | 72.31% | 71.18% | 69.47% | 68.02% |
| Operating profit margin | -25.58% | -24.15% | -24.73% | -24.71% | -21.12% | -23.00% | -23.45% | -21.49% | -22.27% | -26.38% | -26.60% | -29.85% | -33.39% | -3.96% | -5.43% | -7.11% | -7.80% | -15.29% | 2.89% | 15.45% |
| Pretax margin | -17.38% | -14.53% | -13.83% | -12.87% | 18.72% | 19.15% | 19.22% | 19.15% | 16.67% | 16.47% | 16.21% | 15.41% | 17.42% | -9.31% | -9.31% | -9.47% | -16.21% | 8.72% | 7.23% | 8.60% |
| Net profit margin | -18.53% | -15.30% | -14.06% | -13.50% | 17.83% | 18.44% | 17.62% | 15.95% | 13.71% | 14.29% | 14.04% | 13.31% | 15.08% | -11.89% | -11.44% | -14.53% | -21.20% | -0.11% | -1.61% | 3.08% |
The profitability ratios of Bristol-Myers Squibb Company have shown fluctuations over the years based on the provided data.
1. Gross Profit Margin: The company's gross profit margin was relatively high, ranging from 68.02% to 72.31% between March 2020 and December 2020. However, there was a notable decline in the margin from March 2021 to December 2024, with the margin dropping to as low as 34.43% in December 2024.
2. Operating Profit Margin: Bristol-Myers Squibb experienced mixed performance in terms of operating profit margin, with negative margins reported from September 2020 to December 2024. The lowest operating profit margin was recorded in December 2024 at -25.58%.
3. Pretax Margin: The pretax margin of the company also varied significantly over time. After a period of negative margins, there was a notable recovery from March 2022 to December 2023, reaching a high of 19.15% in September 2023. However, the margin dropped again to -17.38% by December 2024.
4. Net Profit Margin: Bristol-Myers Squibb's net profit margin exhibited a similar trend to the pretax margin, with negative margins during certain periods. The company saw improvements in its net profit margin from March 2022 to September 2023, reaching a peak of 18.44% in September 2023. Nevertheless, the margin decreased to -18.53% by December 2024.
Overall, Bristol-Myers Squibb Company has experienced volatility in its profitability ratios, with fluctuations in gross profit margin, operating profit margin, pretax margin, and net profit margin over the analyzed period.
Return on investment
| Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating return on assets (Operating ROA) | -13.34% | -12.23% | -12.15% | -11.36% | -9.99% | -11.33% | -11.34% | -10.45% | -10.62% | -12.56% | -12.49% | -13.60% | -14.17% | -1.62% | -2.18% | -2.71% | -2.80% | -4.80% | 0.79% | 3.70% |
| Return on assets (ROA) | -9.66% | -7.75% | -6.91% | -6.21% | 8.43% | 9.08% | 8.52% | 7.75% | 6.53% | 6.80% | 6.59% | 6.07% | 6.40% | -4.87% | -4.58% | -5.53% | -7.61% | -0.04% | -0.44% | 0.74% |
| Return on total capital | -31.29% | -21.99% | -14.47% | -6.91% | 14.51% | 15.95% | 14.78% | 14.91% | 13.50% | 12.86% | 12.81% | 12.38% | 12.46% | -3.73% | -3.46% | -3.22% | -6.35% | 5.22% | 4.10% | 3.92% |
| Return on equity (ROE) | -54.78% | -42.34% | -38.44% | -37.28% | 27.27% | 28.57% | 24.91% | 22.97% | 20.37% | 20.44% | 20.30% | 19.79% | 19.46% | -14.52% | -13.80% | -16.54% | -23.84% | -0.09% | -1.15% | 1.91% |
The profitability ratios of Bristol-Myers Squibb Company have shown mixed performance over the analyzed periods.
1. Operating return on assets (Operating ROA):
- The company's Operating ROA fluctuated between positive and negative values, indicating fluctuating profitability from operating activities in relation to its total assets.
- The ratio ranged from a high of 3.70% in March 2020 to a low of -13.60% in March 2022, with a slight improvement to -9.99% by December 2023.
- Overall, the trend suggests inconsistent operational efficiency in generating profits relative to the company's asset base.
2. Return on assets (ROA):
- The ROA also varied widely, with negative returns in several periods, signaling challenges in generating profits from its total assets.
- The ratio ranged from a low of -9.66% in December 2024 to a high of 9.08% in September 2023, reflecting significant fluctuations in profitability efficiency.
- The ROA exhibited improvement from negative figures to positive values over the analysis period, although there were periods of decline as well.
3. Return on total capital:
- Return on total capital depicted a similar pattern of fluctuation, with the ratio swinging between positive and negative values.
- The metric ranged from a low of -31.29% in December 2024 to a peak of 15.95% in September 2023, illustrating considerable variability in the company's ability to generate returns from its total capital.
- The performance improved in the latter periods compared to the earlier years, indicating enhanced utilization of the total capital invested.
4. Return on equity (ROE):
- ROE displayed a wide range of fluctuations over the analyzed periods, indicating varying returns to the company's equity shareholders.
- The ratio ranged from a low of -54.78% in December 2024 to a high of 28.57% in September 2023, reflecting the volatility in profitability relative to shareholder equity.
- While the ROE trended upwards from negative figures to positive values over time, there were periods of substantial decline, particularly in the latter periods.
In summary, Bristol-Myers Squibb Company's profitability ratios demonstrate a fluctuating performance, with periods of both improvement and deterioration in operational efficiency and returns to various sources of capital. It is crucial for the company to focus on consistent profitability and efficient asset utilization to enhance overall financial performance and stakeholder value.
See also:
Bristol-Myers Squibb Company Profitability Ratios (Quarterly Data)